ARENA - Project Atrial Fibrilation Rhine-Neckar Region
Last updated on July 2021Recruitment
- Recruitment Status
- Active, not recruiting
- Estimated Enrollment
- 10000
Summary
- Conditions
- Atrial Fibrillation
- Design
- Observational Model: CohortTime Perspective: Prospective
Participation Requirements
- Age
- Between 18 years and 100 years
- Gender
- Both males and females
Description
ARENA aims to inform patients about the symptoms and the risks of atrial fibrilation. The study design includes three study arms: ARENA Intervention: This project will examine the effectiveness of population education and other measures to provide care for patients with atrial fibrillation. In the e...
ARENA aims to inform patients about the symptoms and the risks of atrial fibrilation. The study design includes three study arms: ARENA Intervention: This project will examine the effectiveness of population education and other measures to provide care for patients with atrial fibrillation. In the end of the control phase (1 year recruitment of approximately 10,000 patients), there will be a wide publicity, informing about the disease. ARENA Medication: ARENA records the patient's complete medication at all survey times (up to two weeks after recruitment and follow up). This allows an accurate assessment of interactions between individual substances. In addition, attempts are being made to determine drug concentrations of anticoagulants directly by the blood of the patient. Therefore, patients are provided with kits, which they can use to apply a drop of blood from your fingertip to a filter paper. The aim is to examine the patient's adherence and to analyze whether there are any complications. ARENA Migration: The Metropolregion Rhein-Neckar is characterized by a high proportion of people with a Turkish migration background. ARENA migration aims to examine whether a targeted population education can improve the care of this patient group.
Tracking Information
- NCT #
- NCT02978248
- Collaborators
- Not Provided
- Investigators
- Principal Investigator: Martin Borggrefe, Prof. Dr. Universitätsmedizin Mannheim Study Chair: Walter E. Haefeli, Prof. Dr. University Hospital Heidelberg Study Chair: Ömer Sanatci, Dr. med. Praxis Merz Sanatci